SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Art Pappas will sit on a panel titled "Getting the Funds You Need to Build and Grow Your Company" at the Specialty Pharmaceutical Conference sponsored by the Institute for International Research in Orlando.
News | 04. 11. 2007
